SCHEDULE 13D: Major Investor Group Increases Stake in I-MAB, Files Schedule 13D

A group of investment entities and individuals, led by Wei Fu, has significantly increased their beneficial ownership in I-MAB, triggering a Schedule 13D filing with the SEC.

Summary

• A group of thirteen reporting persons, including CBC Investment I-Mab Limited, IBC Investment Seven Limited, and C-Bridge Healthcare Fund II, L.P., along with individual Wei Fu, have filed a Schedule 13D.
• The filing indicates that the reporting persons' aggregate beneficial ownership of I-MAB's Ordinary Shares, including those underlying American Depository Shares (ADSs), has exceeded the 2% threshold within the preceding 12 months, necessitating the switch from a Schedule 13G.
• Wei Fu, a citizen of Singapore, is deemed to beneficially own the largest stake among the reporting persons, holding 33,571,163 ordinary shares, which represents 17.9% of the Issuer's outstanding ordinary shares.
• Nova Aqua Limited, one of the reporting persons, purchased an aggregate of 1,792,508 ADSs between January 6, 2025, and January 30, 2025, at prices ranging from $0.97 to $1.39 per ADS, totaling an aggregate purchase price of $2,006,282.83.
• The source of funds for these acquisitions came from capital contributions of the Reporting Persons and/or their respective partners or members.
• The reporting persons state their purpose for the investment is to increase the value of their investments and the Issuer.
• The filing also details existing registration rights (Demand, Form F-3, and Piggyback) granted to certain investors under a Fourth Amended and Restated Shareholders Agreement from July 25, 2019, which terminated upon the Issuer's IPO in 2019, but the registration rights remain active until January 22, 2030, or earlier under specific conditions.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The increased stake by a large investor group, explicitly for investment purposes to increase value, suggests confidence. However, the stated flexibility to dispose of shares or pursue extraordinary transactions introduces some uncertainty.

Positives

• Increased stake by a significant investor group, including Wei Fu, signals confidence in I-MAB's business and prospects.
• The investment is explicitly stated to be for 'investment purposes with the aim of increasing the value of their investments and the Issuer,' suggesting alignment with long-term shareholder value.

Negatives

• The filing indicates the possibility that the reporting persons may dispose of all or a portion of their securities at any time, which could introduce selling pressure.
• The reporting persons reserve the right to propose or participate in future transactions, including extraordinary corporate transactions like mergers, reorganizations, or liquidations, which could lead to significant changes for the company.

Risks

• The reporting persons may increase or decrease their holdings, potentially impacting share price volatility.
• The possibility of the reporting persons proposing or participating in extraordinary corporate transactions (e.g., merger, reorganization, liquidation, sale of material assets) introduces strategic uncertainty for the Issuer.
• The reporting persons retain the right to change their investment intent at any time, which could lead to unexpected shifts in their strategy regarding I-MAB.

Future Outlook

The reporting persons intend to continue holding their investment for value appreciation and may purchase additional securities or dispose of existing holdings based on their evaluation of I-MAB's business, market conditions, and other opportunities. They also reserve the right to propose or participate in future extraordinary corporate transactions, including mergers, reorganizations, or liquidations.

Management Comments

• "The Reporting Persons purchased the aforementioned securities for investment purposes with the aim of increasing the value of their investments and the Issuer."
• "Subject to applicable legal requirements, one or more of the Reporting Persons may purchase additional securities of the Issuer from time to time in open market or private transactions, depending on its evaluation of the Issuer's business, prospects and financial condition, the market for the Issuer's securities, other developments concerning the Issuer, the reaction of the Issuer to the Reporting Persons' ownership of the Issuer's securities, other opportunities available to the Reporting Persons, and general economic, money market and stock market conditions."
• "In addition, depending upon the factors referred to above, the Reporting Persons may dispose of all or a portion of their securities of the Issuer at any time."
• "Each of the Reporting Persons reserve the right to increase or decrease its holdings on such terms and at such times as each may decide."
• "Each of the Reporting Persons reserves the right to propose or participate in future transactions which may result in one or more of such actions, including but not limited to, an extraordinary corporate transaction, such as a merger, reorganization or liquidation, sale of a material amount of assets of the Issuer or its subsidiaries, or other transactions which might have the effect of causing the Common Stock to become eligible for termination of registration under Section 12(g) of the Act."
• "The Reporting Persons also retain the right to change their investment intent at any time, to acquire additional shares of Common Stock or other securities of the Issuer from time to time, or to sell, distribute or otherwise dispose of all or part of the Common Stock beneficially owned by them in any manner permitted by law."

Industry Context

This filing reflects a significant increase in a strategic investor group's stake in I-MAB, a biopharmaceutical company. Such increased ownership by a major investment group, particularly one with a focus on healthcare like C-Bridge, could signal a belief in the company's long-term potential within the competitive pharmaceutical and biotechnology industry, especially in China and Asian Pacific markets where Everest Medicines Limited (part of the group) operates.

Corporate Governance

Related Party Transactions

• The document details the intricate control structure among the reporting persons, where various entities are controlled by C-Bridge Healthcare Fund II, L.P., I-Bridge Healthcare Fund, L.P., and ultimately by Mr. Wei Fu. Nova Aqua Limited is held through a trust established by Mr. Wei Fu for the benefit of himself and his family. Everest Medicines Limited is controlled by funds under common control of the C-Bridge group, which is controlled by Mr. Wei Fu. These relationships indicate a network of related entities acting in concert regarding the investment in I-MAB.

Stakeholder Impact

• **Shareholders**: The increased stake by a major investor group could be seen as a positive signal, potentially boosting investor confidence. However, the stated flexibility of the reporting persons to buy or sell shares, or to pursue extraordinary transactions, introduces potential volatility and strategic uncertainty.
• **Management**: The significant ownership stake by this group, particularly with the stated intent to increase the Issuer's value and the reservation of rights to propose corporate transactions, could lead to increased engagement or influence from the reporting persons on the company's strategic direction.

Next Steps

• Reporting persons may purchase additional securities of I-MAB in open market or private transactions.
• Reporting persons may dispose of all or a portion of their securities of I-MAB.
• Reporting persons may propose or participate in future extraordinary corporate transactions, such as a merger, reorganization, or liquidation.
• The Issuer may be requested to effect demand, Form F-3, or piggyback registrations for the reporting persons' registrable securities, subject to the terms of the Shareholders Agreement.

Key Dates

Keywords

I-MAB, Schedule 13D, Beneficial Ownership, SEC Filing, Investment, Shareholder Agreement, Registration Rights, ADS, Ordinary Shares, Wei Fu, CBC Group, C-Bridge Healthcare